Features of management of patients with liver diseases in the conditions of the COVID-19 pandemic

Abstract

Liver dysfunction is common with COVID-19 infection, and the prevalence is higher in men as well as in the elderly. Manifestations of liver damage such as high aspartate aminotransferase and alanine aminotransferase activity, increased bilirubin levels, low albumin levels, and prolonged prothrombin time are associated with severe COVID-19 infection. Mortality in patients with diffuse liver diseases without cirrhosis with COVID-19 infection was 12 %, in the presence of liver cirrhosis — up to 40%, decompensated liver cirrhosis — up to 43–63%. The mechanisms of liver damage in COVID-19 include direct hepatotoxicity and indirect liver damage (due to systemic inflammation with impaired immunity, sepsis, hypoxia, ischemia, coagulopathy, endotheliitis, right ventricular failure, worsening of the course of existing liver diseases, drug liver damage). Treatment of patients with diffuse liver diseases includes lifestyle and nutritional modification, the use of hepatoprotective drugs, and means of correcting the intestinal barrier (bibliography: 30 refs).

Keywords

hepatoprotectors / liver cirrhosis / liver damage / new coronavirus infection

References

[1] Grinevich VB, Gubonina IV, Doshchitsin VL. and others. Peculiarities of management of comorbid patients during a pandemic of a new coronavirus infection (COVID-19). National Consensus 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630. DOI: 10.15829/1728-8800-2020-2630 (In Russ.)

[2] Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный консенсус 2020 // Кардиоваскулярная терапия и профилактика. 2020. Т. 19, № 4. С. 2630. DOI: 10.15829/1728-8800-2020-2630

[3] Grinevich VB, Kravchuk YuA, Ped VI, et al. Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia. 2nd ed. Experimental and Clinical Gastroenterology. 2021;(3):5–82. DOI: 10.31146/1682-8658-ecg-187-3-5-82 (In Russ.)

[4] Гриневич В.Б., Кравчук Ю.А., Педь В.И. и др. Ведение пациентов с заболеваниями органов пищеварения в период пандемии COVID-19. Клинические рекомендации Российского научного медицинского общества терапевтов и Научного общества гастроэнтерологов России. 2-е изд. // Экспериментальная и клиническая гастроэнтерология. 2021. № 3. С. 5–82. DOI: 10.31146/1682-8658-ecg-187-3-5-82

[5] Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020;77:18–24. DOI: 10.1016/j.ejim.2020.05.03

[6] Portincasa P., Krawczyk M., Machill A., et al. Hepatic consequences of COVID-19 infection. Lapping or biting? // Eur. J. Intern. Med. 2020. No. 77. P. 18–24. DOI: 10.1016/j.ejim.2020.05.03

[7] Amin M. COVID-19 and the liver: overview. Eur J Gastroenterol Hepatol. 2021;33(3):309–311. DOI: 10.1097/MEG.0000000000001808

[8] Amin M. COVID-19 and the liver: overview // Eur. J. Gastroenterol. Hepatol. 2021. Vol. 33, No. 3. P. 309–311. DOI: 10.1097/MEG.0000000000001808

[9] Cai Q, Huang D. Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73(3):566–574. DOI: 10.1016/j.jhep.2020.04.006

[10] Cai Q., Huang D., Yu H., et al. COVID-19: Abnormal liver function tests // J. Hepatol. 2020. Vol. 73, No. 3. P. 566–574. DOI: 10.1016/j.jhep.2020.04.006

[11] Feng G, Zheng KI, Yan QQ, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020;8(1):18–24. DOI: 10.14218/JCTH.2020.00018

[12] Feng G., Zheng K.I., Yan Q.Q., et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies // J. Clin. Transl. Hepatol. 2020. Vol. 8, No. 1. P. 18–24. DOI: 10.14218/JCTH.2020.00018

[13] Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. DOI: 10.1111/LIV.14470

[14] Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease // Liver Int. DOI: 10.1111/LIV.14470

[15] Parohan M, Yaghoubi S, Seraji A. Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. Hepatol Res. 2020;50(8):924–935. DOI: 10.1111/hepr.13510

[16] Parohan M., Yaghoubi S., Seraji A. Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies // Hepatol. Res. 2020. Vol. 50, No. 8. P. 924–935. DOI: 10.1111/hepr.13510

[17] Kumar A, Arora A, Sharma P, et al. Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. Indian J Gastroenterol. 2020;39(3):268–284. DOI: 10.1007/s12664-020-01058-3

[18] Kumar A., Arora A., Sharma P., et al. Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis // Indian J. Gastroenterol. 2020. Vol. 39, No. 3. P. 268–284. DOI: 10.1007/s12664-020-01058-3

[19] Dong ZY, Xiang BJ, Jiang M, Sun MJ, Dai C. The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2021;55(1):67–76. DOI: 10.1097/MCG.0000000000001424

[20] Dong Z.Y., Xiang B.J., Jiang M., Sun M.J., Dai C. The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta-Analysis // J. Clin. Gastroenterol. 2021. Vol. 55, No. 1. P. 67–76. DOI: 10.1097/MCG.0000000000001424

[21] Wang H, Qiu P, Liu J, Wang F, Zhao Q. The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020;44(5):653–661. DOI: 10.1016/j.clinre.2020.04.012

[22] Wang H., Qiu P., Liu J., Wang F., Zhao Q. The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis // Clin. Res. Hepatol. Gastroenterol. 2020. Vol. 44, No. 5. P. 653–661. DOI: 10.1016/j.clinre.2020.04.012

[23] Wong YJ, Tan M, Zheng Q, et al. A systematic review and meta-analysis of the COVID-19 associated liver injury. Ann Hepatol. 2020;19(6):627–634. DOI: 10.1016/j.aohep.2020.08.064

[24] Wong Y.J., Tan M., Zheng Q., et al. A systematic review and meta-analysis of the COVID-19 associated liver injury // Ann. Hepatol. 2020. Vol. 19, No. 6. P. 627–634. DOI: 10.1016/j.aohep.2020.08.064

[25] Wu Y, Li H, Guo X, et al. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):621–637. DOI: 10.1007/s12072-020-10074-6

[26] Wu Y., Li H., Guo X., et al. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis // Hepatol. Int. 2020. Vol. 14, No. 5. P. 621–637. DOI: 10.1007/s12072-020-10074-6

[27] Nasa P, Alexander G. COVID-19 and the liver: What do we know so far? World J Hepatol. 2021;13(5):522–532. DOI: 10.4254/wjh.v13.i5.522

[28] Nasa P., Alexander G. COVID-19 and the liver: What do we know so far? // World J. Hepatol. 2021. Vol. 13, No. 5. P. 522–532. DOI: 10.4254/wjh.v13.i5.522

[29] Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–292.e6. DOI: 10.1016/j.cell.2020.02.058

[30] Walls A.C., Park Y.J., Tortorici M.A., et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein // Cell. 2020. Vol. 181, No. 2. P. 281–292.e6. DOI: 10.1016/j.cell.2020.02.058

[31] Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv. DOI: 10.1101/2020.02.03.931766

[32] Chai X., Hu L., Zhang Y., et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection // bioRxiv. DOI: 10.1101/2020.02.03.931766

[33] Sridhar S, Nicholls J. Pathophysiology of infection with SARS-CoV-2 – What is known and what remains a mystery. Respirology. 2021;26(7):652–665. DOI: 10.1111/resp.14091

[34] Sridhar S., Nicholls J. Pathophysiology of infection with SARS-CoV-2 – What is known and what remains a mystery // Respirology. 2021. Vol. 26, Issue 7. P. 652–665. DOI: 10.1111/resp.14091

[35] Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790–1796. DOI:10.1136/gut.2004.062398

[36] Paizis G., Tikellis C., Cooper M.E., et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2 // Gut. 2005. Vol. 54, No. 12. P. 1790–1796. DOI: 10.1136/gut.2004.062398

[37] Albillos A, Lario M, Álvarez-Mon M. Cirrhosisassociated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology. 2014;(61):1385–1396.

[38] Albillos A., Lario M., Álvarez-Mon M. Cirrhosisassociated immune dysfunction: Distinctive features and clinical relevance // Journal of Hepatology 2014. No. 61. P. 1385–1396.

[39] Gao F, Zheng KI, Wang XB, et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol. 2021;36(1):204–207. DOI: 10.1111/ jgh.15112

[40] Gao F., Zheng K.I., Wang X.B., et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients // J. Gastroenterol. Hepatol. 2021. Vol. 36, No. 1. P. 204–207. DOI: 10.1111/ jgh.15112

[41] Moon AM, Webb GJ, Aloman C, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020;73(3):705–708. DOI: 10.1016/j.jhep.2020.05.013

[42] Moon A.M., Webb G.J., Aloman C., et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry // J. Hepatol. 2020. Vol. 73, No. 3. P. 705–708. DOI: 10.1016/j.jhep.2020.05.013

[43] Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451–458. DOI: 10.4065/mcp.2009.0534

[44] Chandok N., Watt K.D. Pain management in the cirrhotic patient: the clinical challenge // Mayo Clin Proc. 2010. Vol. 85, No. 5. P. 451–458. DOI: 10.4065/mcp.2009.0534

[45] Mayevskaya MV, Nadinskaia MYu, Lunkov VD, et al. An effect of ursodeoxycholic acid on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease: results of the uspeh study. Ros J Gastroenterol Gepatol Coloproctol. 2019;29(6):22–29. DOI: 10.22416/1382-4376-2019-29-6-22-29 (In Russ.)

[46] Маевская М. В., Надинская М. Ю., Луньков В. Д., и др. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019. Т. 29, № 6. С. 22–29. DOI: 10.22416/1382-4376-2019-29-6-22-29

[47] Mroz MS, Harvey BJ. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fi brosis bronchial epithelial cells. Steroids. 2019;(151):108461. DOI: 10.1016/j.steroids.2019.108461

[48] Mroz M.S., Harvey B.J. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fi brosis bronchial epithelial cells // Steroids. 2019. No. 151. P. 108461. DOI: 10.1016/j.steroids.2019.108461

[49] Işık S, Karaman M, Çilaker Micili S, et al. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017;45(4): 339–349. DOI: 10.1016/j.aller.2016.12.003

[50] Işık S., Karaman M., Çilaker Micili S., et al. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma // Allergol. Immunopathol. (Madr). 2017. Vol. 45, No. 4. P. 339–349. DOI: 10.1016/j.aller.2016.12.003

[51] Press release of the RSA and ROPIP. New disease, new symptoms, new therapeutic options. 2021. Available at: https://www.rsls.ru/files/Prz2.pdf (access 10.06.2021) (In Russ.)

[52] Пресс-релиз РГА и РОПИП. Новое заболевание, новые симптомы, новые терапевтические возможности. 2021. Доступен по: https://www.rsls.ru/files/Prz2.pdf (дата обращения 10.06.2021)

[53] Shapovalov KG, Tsydenpinov GA, Lukyanov SA, et al. Prospects for the use of succinates in the severe course of a new coronavirus infection. Experimental and Clinical Pharmacology. 2020;83(10): 40–43. (In Russ.)

[54] Шаповалов К.Г., Цыденпинов Г.А., Лукьянов С.А., и др. Перспективы применения сукцинатов при тяжелом течении новой коронавирусной инфекции // Экспериментальная и клиническая фармакология. 2020. Т. 83, № 10. С. 40–43.

[55] Lazebnik LB, Golovanova EV, Alekseenko SA, et al. Russian consensus “Hyperammonemia in adults” Approved as a document of the Russian Scientific Medical Society of Physicians (RNMOT) and the Scientific Society of Gastroenterologists of Russia (NOGR) November 20–21, 2019 by the XIV National Congress of Physicians and XXII Congress of the NOGR. Therapy. 2020; (4):26–51. (In Russ.)

[56] Лазебник Л.Б., Голованова Е.В., Алексеенко С.А., и др. Российский консенсус «Гипераммониемии у взрослых» Утвержден в качестве документа Российского научного медицинского общества терапевтов (РНМОТ) и Научного общества гастроэнтерологов России (НОГР) 20–21 ноября 2019 г. XIV Национальным конгрессом терапевтов и XXII съездом НОГР // Терапия. 2020. № 4. C. 26–51.

[57] Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Med Sci. 2019;7(6):2482–2493, DOI: 10.18203/2320-6012.ijrms20192550

[58] Saigal S., Kapoor D., Roy D.S. Ademetionine in patients with liver disease: a review // Int. J. Res. Med. Sci. 2019. Vol. 7, No. 6. P. 2482–2493, DOI: 10.18203/2320-6012.ijrms20192550

[59] Maksimov VA, Torshin IYu, Chuchalin AG, et al. Efficacy and safety of a polypeptide drug (Laennec) in the therapy of COVID-19. Experimental and Clinical Gastroenterology. 2020;178(6):55–63. DOI: 10.31146/1682-8658-ecg-178-6-55-63 (In Russ.)

[60] Максимов В.А., Торшин И.Ю., Чучалин А.Г., и др. Эффективность и безопасность полипептидного препарата (Лаеннек) в терапии COVID-19 // Экспериментальная и клиническая гастроэнтерология. 2020. Т. 178, № 6. С. 55–63. DOI: 10.31146/1682-8658-ecg-178-6-55-63

RIGHTS & PERMISSIONS

Kravchuk Y.A.